From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
Response to gefitinib
Response to 2nd gefitinib
Author
No. of patients
CR/PR/SD
PD
Yokouchi H et al.
9
-
8
1
Yoshimoto A et al.
0
Yano S et al.
3
2
Hashimoto N et al.
Kurata T et al.